Pfizer Inc. $PFE Shares Sold by State of Michigan Retirement System

Key Points

• State of Michigan Retirement System trimmed its Pfizer stake by 2.3%, selling 38,500 shares and now holds 1,670,184 shares valued at about $41.59 million.
• Pfizer beat Q4 estimates, reporting $0.66 EPS versus $0.57 expected and $17.56 billion in revenue, though revenue was down 1.2% year‑over‑year and net margin was 12.42%.
• The board declared a $0.43 quarterly dividend (annualized $1.72, ~6.4% yield; ex‑div May 8, payable June 12) despite a 126.47% payout ratio, while analysts hold a consensus "Hold" rating with an average price target of $28.48 and mixed outlooks on Pfizer's pipeline and growth catalysts.

State of Michigan Retirement System lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,670,184 shares of the biopharmaceutical company's stock after selling 38,500 shares during the period. State of Michigan Retirement System's holdings in Pfizer were worth $41,588,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Horizon Financial Services LLC grew its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 645 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Pfizer in the 4th quarter valued at about $28,000. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the third quarter worth about $29,000. Darwin Wealth Management LLC bought a new position in shares of Pfizer during the second quarter worth about $32,000. Finally, True Wealth Design LLC grew its stake in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 974 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.0%

Pfizer stock opened at $27.01 on Monday. Pfizer Inc. has a 52 week low of $21.97 and a 52 week high of $28.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The firm has a market capitalization of $153.56 billion, a price-to-earnings ratio of 19.86 and a beta of 0.43. The company has a 50 day moving average price of $27.23 and a 200 day moving average price of $26.06.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company's revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.63 EPS. Research analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's payout ratio is presently 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; ex-div May 8), reinforcing Pfizer’s long track record of income (350th consecutive quarterly dividend) and supporting demand from income-minded investors. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Seagen acquisition appears to be contributing to growth and a stronger oncology franchise (Antibody‑Drug Conjugates), supporting medium-term revenue upside as Pfizer expands cancer capabilities. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: GLP‑1 obesity program momentum — Phase 2b monthly GLP‑1 data and plans for a large clinical program provide optionality beyond legacy drugs and could open a new growth engine if later‑stage trials succeed. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Positive Sentiment: Multiple early‑stage pipeline advances (completion of a China Phase 1 for a heart‑failure candidate, new gastric‑emptying study for an obesity asset, new Phase 1 cancer and liver studies) add cadence and long‑term upside to the pipeline. Pfizer Advances Early-Stage Heart Failure Candidate With Completion Of Chinese Phase 1 Study
• Neutral Sentiment: Pfizer released results from its 2026 shareholder meeting — largely procedural items that don’t materially change near‑term fundamentals. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Bristol Myers and Pfizer will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27 — improves patient access but raises questions about pricing/volume tradeoffs; watch margin impact. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
• Neutral Sentiment: Broader industry news — competitors (e.g., Eli Lilly, Novo Nordisk) continue to shape the obesity/GLP‑1 landscape; this is both competitive risk and market validation for Pfizer’s obesity push. Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
• Negative Sentiment: Pfizer ended a Phase 1 cancer trial, trimming part of its oncology pipeline — a reminder that not all program investments convert to later‑stage value and a near‑term negative headline. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism persists (Barclays remains negative; consensus leans to “hold”), which can cap upside until clearer revenue/cost trajectories emerge. Barclays Remains a Sell on Pfizer (PFE)

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. Daiwa Securities Group downgraded Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Royal Bank Of Canada restated an "underperform" rating and issued a $25.00 target price on shares of Pfizer in a report on Monday, April 20th. BMO Capital Markets reaffirmed an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. CICC Research started coverage on Pfizer in a report on Thursday, April 16th. They set an "outperform" rating and a $33.00 target price for the company. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and an average price target of $28.48.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.